Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vimal H Prajapati

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Journal of the American Academy of Dermatology|August 25, 2024
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
American Journal of Clinical Dermatology|February 3, 2025
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective StudySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|February 15, 2025
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Siddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|April 22, 2024
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective studyAlexander Rimke, Siddhartha Sood, Brian D Rankin, et al.
Dermatology and Therapy|October 9, 2025
Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative ReviewCharles W Lynde, Vimal H Prajapati, Melinda J Gooderham, et al.
Pediatric Dermatology|October 31, 2023
Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumabSylvia Martinez-Cabriales, Danielle Marcoux, Carmen Liy-Wong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2024
Considerations for defining and diagnosing generalized pustular psoriasisVimal H Prajapati, Charles W Lynde, Melinda J Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Journal of the American Academy of Dermatology|August 25, 2024
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective reviewSiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
American Journal of Clinical Dermatology|February 3, 2025
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective StudySiddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|February 15, 2025
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"Siddhartha Sood, Alexander Rimke, Brian D Rankin, et al.
Journal of the American Academy of Dermatology|April 22, 2024
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective studyAlexander Rimke, Siddhartha Sood, Brian D Rankin, et al.
Dermatology and Therapy|October 9, 2025
Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative ReviewCharles W Lynde, Vimal H Prajapati, Melinda J Gooderham, et al.
Pediatric Dermatology|October 31, 2023
Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumabSylvia Martinez-Cabriales, Danielle Marcoux, Carmen Liy-Wong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2024
Considerations for defining and diagnosing generalized pustular psoriasisVimal H Prajapati, Charles W Lynde, Melinda J Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 24, 2024
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective ReviewBrian D Rankin, Siddhartha Sood, Ye-Jean Park, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Pageof 11